Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer.

Next Previous
X
Search
Trial Profile

Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Samarium 153 lexidronam (Primary) ; Calcium; Strontium-89; Vitamin D analogues; Zoledronic acid
  • Indications Advanced breast cancer; Bone metastases; Lung cancer; Prostate cancer
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 03 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 01 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Additional lead trial investigators identified as reported by New Jersey Cancer Trial Connect.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top